Holen Sie sich die Stockscreener-App
1.17
16.43%
-0.23
Handel nachbörslich:
1.18
0.01
+0.85%
Biovie Inc Aktie (BIVI) Neueste Nachrichten
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - New Castle News
BioVie Phase 2b Parkinson’s Trial Meets Primary Endpoint - Minichart
BioVie Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 - marketscreener.com
These stocks have an unusual volume in today's session - ChartMill
BioVie Q4 Results: EPS loss narrows 51% YoY to $(0.70) - scanx.trade
BIVI Stock Jumps As SUNRISE-PD Data Fuels Parkinson’s Hopes - timothysykes.com
BIOVIE INC. FY 2026: Net loss $22.1M — 10-K Summary - TradingView
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
BIVI Stock Jumps As SUNRISE-PD Data Fire Up Parkinson’s Hopes - StocksToTrade
BIVI Stock Jumps As SUNRISE-PD Data Ignites Parkinson’s Hopes - timothysykes.com
These stocks are the most active in today's session - ChartMill
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why BioVie (BIVI) Stock Is Up Today - Quiver Quantitative
BioVie Inc. Revenue Breakdown – NASDAQ:BIVIW - TradingView
BioVie Inc (BIVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
New to The Street NASDAQ MARKETSITE - ACCESS Newswire
New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results - newswire.com
Biovie Stock Price Forecast. Should You Buy BIVI? - StockInvest.us
Morgan Stanley (BIVI) discloses 896,822 BioVie shares, an 11.9% stake - Stock Titan
Morgan Stanley (BIVI) discloses 8.0% beneficial stake in BioVie Class A shares - Stock Titan
BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver disease - Bitget
BioVie Inc (BIVI) Stock News Today - TradingKey
Parkinson's drug developers are betting big on inflammation - Proactive financial news
Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results - finance.yahoo.com
BioVie stock sinks on Phase IIb Parkinson’s trial data - Yahoo Finance
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease - markets.businessinsider.com
BioVieBezisterim Shows Statistically Signi - Moomoo
BioVie reports positive phase 2 trial results for Parkinson’s drug By Investing.com - Investing.com South Africa
BioVie shares halve on murky Parkinson’s disease readout - BioSpace
BioVie reports positive phase 2 trial results for Parkinson’s drug - Investing.com
BioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s program - Fierce Biotech
BIVI Stock Slides As New Equity Offering Looms Over Traders - StocksToTrade
BioVie Announces Positive Phase 2 Parkinson’s Trial Results - TipRanks
Form 8K Biovie Inc For: 6 August By Investing.com - Investing.com Canada
BioVie reports positive Phase 2 SUNRISE-PD topline results for bezisterim showing clinical and biomarker gains - TradingView
BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim - Proactive financial news
BioVie posts corporate presentation outlining bezisterim and BIV201 clinical programs - Bitget
BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial - Yahoo Finance
BioVie Shareholder Notice - TMX Newsfile
BioVie Ongoing Deadline Alert - TMX Newsfile
BioVie Inc. (BIVI) Climbs 6.29% to $1.52 as Momentum Builds Toward $1.60 ResistanceDaily Profile - dars.gov.et
[S-1/A] BIOVIE INC. Amends IPO Registration Statement - Stock Titan
BioVie Inc (BIVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioVie Inc (BIVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioVie Inc (BIVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioVie Inc (BIVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BIVI|BioVie Inc|Price:1.400|Chg%:+0.030 - TradingKey
BIVI|BioVie Inc|Price:1.370| - TradingKey
BioVie Inc (BIVI) Earnings Date & Reports & Earnings News - TradingKey
BioVie Inc (BIVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
BioVie Inc (BIVI) Income Statement - TradingKey
BioVie Inc (BIVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioVie Inc (BIVI) Balance Sheet - TradingKey
BioVie Inc. (BIVI) Q2 2026 Earnings: Narrower-Than-Expected Loss as Biotech Advances Clinical PipelineRevenue Miss Report - dars.gov.et
BioVie Inc. Revenue Breakdown – NASDAQ:BIVI - TradingView
BIVI|BioVie Inc|Price:1.370|Chg%:-0.070 - TradingKey
BioVie Inc. (BIVI) Surges 3.88% as Stock Approaches Key ResistanceSmart Money Flow Stocks - dars.gov.et
BioVie Warrants (BIVIW) Hold Steady at $0.53 Amid Tight Trading RangeStrangle Setup - dars.gov.et
12 Health Care Stocks Moving In Monday's Pre-Market SessionAdvanced Biomed (NASDAQ:ADVB), Barinthus Bi - Benzinga
Daily Brief Health Care: JPJ (TCM) Limited(TCM), Abeona Therapeutics , Mani Inc, BioVie , Propanc Biopharma, Tivic Health Systems Inc and more - Smartkarma
IPO Databook: Biovie (BIVI US)Jul 2026 - Smartkarma
BioVie Files for a Stock Offering - Moomoo
[S-1] BIOVIE INC. Files IPO Registration Statement - Stock Titan
Form S-1 Biovie Inc For: 17 July By Investing.com - Investing.com UK
BIVIW SEC FilingsBiovie Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Enterprise value to EBIT forward of BioVie Inc. – NASDAQ:BIVIW - TradingView
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):